John Walter Hanna, Jr. Sells 10,282 Shares of CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. (NASDAQ:CDNA) CEO John Walter Hanna, Jr. sold 10,282 shares of CareDx stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the completion of the transaction, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Price Performance

Shares of NASDAQ CDNA opened at $20.73 on Wednesday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -51.83 and a beta of 2.54. The business has a 50-day moving average of $18.32 and a two-hundred day moving average of $18.00. CareDx, Inc. has a 1 year low of $10.96 and a 1 year high of $23.24.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The business had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The firm’s quarterly revenue was up 25.2% on a year-over-year basis. During the same period last year, the firm earned $0.18 earnings per share. As a group, equities research analysts expect that CareDx, Inc. will post -0.04 earnings per share for the current year.

Institutional Trading of CareDx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of CareDx by 1.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock valued at $739,000 after purchasing an additional 711 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of CareDx by 4.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after purchasing an additional 1,280 shares during the last quarter. Quarry LP purchased a new stake in shares of CareDx in the 4th quarter valued at about $25,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of CareDx by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock valued at $365,000 after purchasing an additional 1,675 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of CareDx in the 3rd quarter valued at about $31,000.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Wells Fargo & Company lifted their price target on CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. BTIG Research lifted their price target on CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings downgraded CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. Finally, Craig Hallum downgraded CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.60.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.